[Federal Register Volume 82, Number 222 (Monday, November 20, 2017)]
[Notices]
[Page 55147]
[FR Doc No: 2017-25041]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-82078; SR-BatsBZX-2017-56]

Self-Regulatory Organizations; Bats BZX Exchange, Inc.; Notice of
Withdrawal of a Proposed Rule Change To List and Trade Shares of
Specified Series of the Innovator Shield Strategy S&P 500 Monthly Index
Series and Innovator Ultra Shield Strategy S&P 500 Monthly Index Series
Under Rule 14.11(c)(3)

November 14, 2017.
    On August 22, 2017, Bats BZX Exchange, Inc. (``Exchange'') filed
with the Securities and Exchange Commission (``Commission''), pursuant
to Section 19(b)(1) of the Securities Exchange Act of 1934 (``Act'')
\1\ and Rule 19b-4 thereunder,\2\ a proposed rule change to list and
trade shares of specified series of the Innovator Shield Strategy S&P
500 Monthly Index Series and Innovator Ultra Shield Strategy S&P 500
Monthly Index Series under BZX Rule 14.11(c)(3). The proposed rule
change was published for comment in the Federal Register on September
5, 2017.\3\ The Commission received no comments on the proposed rule
change. On October 18, 2017, the Commission extended the time period
within which to approve the proposed rule change, disapprove the
proposed rule change, or institute proceedings to determine whether to
approve or disapprove the proposed rule change to December 4, 2017.\4\
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 81495 (August 29,
2017), 82 FR 42003.
    \4\ See Securities Exchange Act Release No. 81895, 82 FR 49252
(October 24, 2017).
---------------------------------------------------------------------------

    On November 8, 2017, the Exchange withdrew the proposed rule change
(SR-BatsBZX-2017-56).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\5\
---------------------------------------------------------------------------

    \5\ 17 CFR 200.30-3(a)(57).
---------------------------------------------------------------------------

Eduardo A. Aleman,
Assistant Secretary.
[FR Doc. 2017-25041 Filed 11-17-17; 8:45 am]
 BILLING CODE 8011-01-P


[Federal Register Volume 77, Number 164 (Thursday, August 23, 2012)]
[Notices]
[Page 51073]
[FR Doc No: 2012-20900]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meeting

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: [77 FR 39749, July
5, 2012].

STATUS: Open Meeting.

PLACE: 100 F Street NW., Washington, DC.

DATE AND TIME OF PREVIOUSLY ANNOUNCED MEETING: August 22, 2012 at 10
a.m.

CHANGE IN THE MEETING: Deletion of an Item.
    The following item will not be considered during the Commission's
Open Meeting on August 22, 2012 at 10 a.m.:

    The Commission will consider rules to eliminate the prohibition
against general solicitation and general advertising in securities
offerings conducted pursuant to Rule 506 of Regulation D under the
Securities Act and Rule 144A under the Securities Act, as mandated
by Section 201(a) of the Jumpstart Our Business Startups Act.

    This item is being rescheduled for consideration at an Open Meeting
on August 29, 2012 as announced in a separate meeting notice.
    At times, changes in Commission priorities require alterations in
the scheduling of meeting items. For further information and to
ascertain what, if any, matters have been added, deleted or postponed,
please contact the Office of the Secretary at<PHONE_NUMBER>.

     Dated: August 21, 2012.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2012-20900 Filed 8-21-12; 4:15 pm]
BILLING CODE 8011-01-P


                 Design Value for air quality monitors in the
                    Fairbanks, AK PM2.5 Nonattainment Area
                          Technical Support Document

Summary
This document provides the Design Value (DV) computation for the North Pole Hurst Road PM2.5 monitoring site which is currently the defining monitoring site for the Fairbanks Nonattainment Area (NAA).  The computation confirms that the Fairbanks NAA is not attaining the 2006 24-hour PM2.5 NAAQS for 2017-19.
Background
Under EPA regulations at 40 CFR part 50, Appendix N, the 2006 primary and secondary 24-hour PM2.5 NAAQS are met within a nonattainment area when the 24-hour PM2.5 NAAQS DV at each eligible monitoring site is less than or equal to 35 μg/m3. Three years of valid annual PM2.5 98th percentile (p98) mass concentrations are required to produce a valid 24-hour PM2.5 NAAQS DV.
The EPA's determination of attainment is based upon data that have been collected and quality-assured in accordance with 40 CFR parts 50 and 58 and recorded in the EPA's AQS database.
Data Quality Review
The 2017 through 2019 ambient concentration and quality assurance data has been certified and uploaded to AQS by Alaska DEC. A data quality review of the Fairbanks PM2.5 data was performed, and it found that the samplers and data met or exceeded data quality criteria specified in 40 CFR parts 50 and 58 for precision, bias, and data completeness.  Based on these results the Fairbanks NAA PM2.5 data has been deemed to be of necessary quality for determining valid DVs for the 2017-19 timeframe.
Design Value Computation
For the 2006 24-hour PM2.5 NAAQS, the 3-year Design Value is calculated as the average of annual p98 values, i.e., DV = [(p98 - year 1) + (p98 - year 2) + (p98 - year 3)] / 3.  The p98 values for the Hurst Road PM2.5 monitors in 2017, 2018, and 2019 are 75.5, 52.8, and 78.3 μg/m3 respectively.   The 2017-19 DV would therefore compute to (75.5 + 52.8 + 78.3)/3 = 206.6/3 = 68.9, which rounds to 69 μg/m3.   As this DV is greater than 35 μg/m3, this confirms that the Fairbanks NAA is not meeting the 2006 24-hr PM2.5 NAAQS based on the most recent three years of certified, quality assured data.


[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Pages 12229-12230]
[FR Doc No: 2017-03944]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Blood Products Advisory
Committee. The general function of the committee is to provide advice
and recommendations to the Agency on FDA's regulatory issues. At least
one portion of the meeting will be closed to the public.

DATES: The meeting will be held on April 4, 2017, from 8:30 a.m. to
3:45 p.m. and on April 5, 2017, from 8:30 a.m. to 12 p.m.

ADDRESSES: The meeting will be held at Tommy Douglas Conference Center,
10000 New Hampshire Ave., Silver Spring, MD 20903. The conference
center's telephone number is<PHONE_NUMBER>. Answers to commonly asked
questions including information regarding special accommodations due to
a disability, visitor parking, and transportation may be accessed at:
http://www.tommydouglascenter.com.

FOR FURTHER INFORMATION CONTACT: Bryan Emery or Joanne Lipkind, Center
for Biologics Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993-
0002,<PHONE_NUMBER>,<PHONE_NUMBER><EMAIL_ADDRESS>
<EMAIL_ADDRESS>or FDA Advisory Committee Information Line,
1-800-741-8138<PHONE_NUMBER> in the Washington, DC area). A notice in
the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting. For those unable to attend in person, the meeting will
also be available via Webcast. The Webcast will be available at the
following link for both days: April 4, 2017, 115th Meeting of the Blood
Products Advisory Committee--Day 1 at: http://fda.yorkcast.com/webcast/Play/bb044b891a7b48ff82cc30b18ece526e1d; April 5, 2017, 115th Meeting
of the Blood Products Advisory Committee--Day 2 at: http://fda.yorkcast.com/webcast/Play/b4068ead1c874966860584b421dcfd231d.

SUPPLEMENTARY INFORMATION:
    Agenda: On April 4, 2017, in open session, the Committee will
discuss Recombinant Human Coagulation Factor IX, GlycoPEGylated. In the
afternoon, in open session, the Committee will hear an update
presentation on a summary of responses to Docket FDA-2016-N-1502: Blood
Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency
Virus Transmission by Blood and Blood Products.
    On April 5, 2017, in open session, the committee will hear overview
presentations on the research programs in the Laboratory of Emerging
Pathogens in the Division of Emerging Transfusion-Transmitted Diseases,
Office of Blood Research and Review, Center for Biologics Evaluation
and Research, FDA. At the conclusion of the open session, the meeting
will be closed to permit discussion where disclosure would constitute
an unwarranted invasion of personal privacy in accordance with 5 U.S.C
552b(c)(6). During the closed session, the Committee will discuss the
research progress made by staff involved in the intramural research
programs and make recommendations regarding their personnel actions and
staffing decisions.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
March 28, 2017. Oral presentations from the public will be scheduled
between approximately 10:50 a.m. to 11:20 a.m. and will be scheduled
between approximately 3:15 p.m. to 3:45 p.m. on April 4, 2017. Oral
presentations from the public will be scheduled between approximately
10:15 a.m. and 11:15 a.m. on April 5, 2017. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before March 20, 2017. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the

speakers for the scheduled open public hearing session. The contact
person will notify interested persons regarding their request to speak
by March 21, 2017.
    Closed Committee Deliberations: On April 5, 2017, from 11:15 a.m.
to 12:00 p.m., the meeting will be closed to permit discussion where
disclosure would constitute a clearly unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The Committee will discuss the report of
the intramural research program and make recommendations regarding
personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Bryan Emery at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: February 24, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-03944 Filed 2-28-17; 8:45 am]
BILLING CODE 4164-01-P